Small-molecule drugs remain the mainstay of cancer therapy but are frequently compromised by poor tumor selectivity and dose-limiting systemic toxicity. Prodrug strategies have therefore been widely developed to improve therapeutic indices; however, convention... ...

请注册登录后继续浏览